Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;11(4):624-634.
doi: 10.1007/s12178-018-9527-7.

Current Clinical Recommendations for Use of Platelet-Rich Plasma

Adrian D K Le  1   2 , Lawrence Enweze  1 , Malcolm R DeBaun  1 , Jason L Dragoo  3
Affiliations
Review

Current Clinical Recommendations for Use of Platelet-Rich Plasma

Adrian D K Le et al. Curr Rev Musculoskelet Med. 2018 Dec.

Abstract

Purpose of review: This review evaluates current clinical literature on the use of platelet-rich plasma (PRP), including leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP), in order to develop evidence-based recommendations for various musculoskeletal indications.

Recent findings: Abundant high-quality evidence supports the use of LR-PRP injection for lateral epicondylitis and LP-PRP for osteoarthritis of the knee. Moderate high-quality evidence supports the use of LR-PRP injection for patellar tendinopathy and of PRP injection for plantar fasciitis and donor site pain in patellar tendon graft BTB ACL reconstruction. There is insufficient evidence to routinely recommend PRP for rotator cuff tendinopathy, osteoarthritis of the hip, or high ankle sprains. Current evidence demonstrates a lack of efficacy of PRP for Achilles tendinopathy, muscle injuries, acute fracture or nonunion, surgical augmentation in rotator cuff repair, Achilles tendon repair, and ACL reconstruction. PRP is a promising treatment for some musculoskeletal diseases; however, evidence of its efficacy has been highly variable depending on the specific indication. Additional high-quality clinical trials with longer follow-up will be critical in shaping our perspective of this treatment option.

Keywords: Orthobiologics; Osteoarthritis; PRP; Platelet-rich plasma; Regenerative medicine; Tendinopathy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Dragoo reports consultancy for Ossur, Genzyme, Depuy/Mitek, Linvatec, Miximed, Zimmer, Harvet/Terumo, and Flexion Therapeutics, grants from Ossur, and educational funding from Linvatec, Smith and Nephew, Breg, and Ossur. All other authors declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy. 2012;28:429–439. - PubMed
    1. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37:2259–2272. - PubMed
    1. Le A, Dragoo JL. Orthobiologics: clinical application of platelet-rich plasma and stem cell therapy. DeLee Drezs Orthop Sports Med. 5th Edition. Elsevier; XXXX p XXX.
    1. • Le AD, Enweze L, DeBaun MR, Dragoo JL. Platelet-rich plasma. Clin Sports Med. 2018;XX:XX–XX. Recent (in-press) comprehensive review of PRP literature outlining best available clinical evidence as well as pre-clinical evidence, where appropriate, for a variety of sports medicine applications.
    1. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10:225–228. - PubMed